Showing results (101-110 of 121) with videos related to
Sort By:
Pageof 13
Cancer Cell|April 13, 2016
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer PatientsNiels Halama, Inka Zoernig, Anna Berthel, et al.Nature Medicine|February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trialBenjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.Journal of Hepatology|February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancerJennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.JCO Precision Oncology|May 26, 2021
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast CancerMario Hlevnjak, Markus Schulze, Shaymaa Elgaafary, et al.Gastroenterology|August 10, 2023
Deep Learning-Enabled Diagnosis of Liver AdenocarcinomaThomas Albrecht, Annik Rossberg, Jana Dorothea Albrecht, et al.International Journal of Cancer|October 31, 2025
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experienceMario Hlevnjak, Sabine Heublein, Verena Thewes, et al.Oncoimmunology|July 3, 2015
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trialFriedrich H Schmitz-Winnenthal, Nicolas Hohmann, Andreas G Niethammer, et al.Translational Oncology|September 1, 2024
Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic responseJingyu An, Roma Kurilov, Teresa Peccerella, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 21, 2024
Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinomaKaiyu Xu, Annika Kessler, Federico Nichetti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaMilind Javle, Maeve Lowery, Rachna T Shroff, et al.Pageof 13